Ragunath Singaravelu

Dr. Ragunath Singaravelu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2011 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
JPJohn Paul Pezacki
John Paul Pezacki
JBJessie A Blake
Jessie A Blake
DDDana C Danielson
Dana C Danielson
DKDavid Kennedy
David Kennedy
RLRodney K Lyn
Rodney K Lyn
RSRagunath Singaravelu
Ragunath Singaravelu
The nonlinear variant of Raman spectroscopy, coherent anti-Stokes Raman scattering (CARS) microscopy, combines powerful Raman signal enhancement with several other advantages such as label-free detection and has been used to image various cellular processes including host-pathogen interactions and lipid metabolism. Cellular biomolecules contain unique molecular vibrations that can be visualized by coherent anti-Stokes Raman scattering (CARS) microscopy without the need for labels. Here we review the application of CARS microscopy for label-free imaging of cells and tissues using the natural vibrational contrast that arises from biomolecules like lipids as well as for imaging of exogenously added probes or drugs. High-resolution CARS microscopy combined with multimodal imaging has allowed for dynamic monitoring of cellular processes such as lipid metabolism and storage, the movement of organelles, adipogenesis and host-pathogen interactions and can also be used to track molecules within cells and tissues. The CARS imaging modality provides a unique tool for biological chemists to elucidate the state of a cellular environment without perturbing it and to perceive the functional effects of added molecules.

29 July 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
RSRagunath Singaravelu
Ragunath Singaravelu
RCRan Chen
Ran Chen
RLRodney K. Lyn
Rodney K. Lyn
DJDaniel M. Jones
Daniel M. Jones
SOShifawn O'Hara
Shifawn O'Hara
JPJohn Paul Pezacki
John Paul Pezacki
MicroRNAs (miRNAs) are small RNAs that posttranscriptionally regulate gene expression. Their aberrant expression is commonly linked with diseased states, including hepatitis C virus (HCV) infection. Herein, we demonstrate that HCV replication induces the expression of miR-27 in cell culture and in vivo HCV infectious models. Overexpression of the HCV proteins core and NS4B independently activates miR-27 expression. Furthermore, we establish that miR-27 overexpression in hepatocytes results in larger and more abundant lipid droplets, as observed by coherent anti-Stokes Raman scattering (CARS) microscopy. This hepatic lipid droplet accumulation coincides with miR-27b's repression of peroxisome proliferator-activated receptor (PPAR)-α and angiopoietin-like protein 3 (ANGPTL3), known regulators of triglyceride homeostasis. We further demonstrate that treatment with a PPAR-α agonist, bezafibrate, is able to reverse the miR-27b-induced lipid accumulation in Huh7 cells. This miR-27b-mediated repression of PPAR-α signaling represents a novel mechanism of HCV-induced hepatic steatosis. This link was further demonstrated in vivo through the correlation between miR-27b expression levels and hepatic lipid accumulation in HCV-infected SCID-beige/Alb-uPa mice. Conclusion : Collectively, our results highlight HCV's up-regulation of miR-27 expression as a novel mechanism contributing to the development of hepatic steatosis.

19 October 2015 in Nature Chemical Biology
Verified
Journal Article
Closed access
RSRagunath Singaravelu
Ragunath Singaravelu
SOShifawn O'Hara
Shifawn O'Hara
DJDaniel M Jones
Daniel M Jones
RCRan Chen
Ran Chen
NTNathan G Taylor
Nathan G Taylor
JPJohn Paul Pezacki
John Paul Pezacki

1 April 2014 in Scientific Reports
Verified
Journal Article
Open access
RLRodney K. Lyn
Rodney K. Lyn
RSRagunath Singaravelu
Ragunath Singaravelu
SKStacia Kargman
Stacia Kargman
SOShifawn O'HAra
Shifawn O'HAra
HCHelen Chan
Helen Chan
JPJohn Paul Pezacki
John Paul Pezacki
Hepatitis C virus (HCV) replication is dependent on the formation of specialized membrane structures; however, the host factor requirements for the formation of these HCV complexes remain unclear. Herein, we demonstrate that inhibition of stearoyl-CoA desaturase 1 (SCD-1) halts the biosynthesis of unsaturated fatty acids, such as oleic acid, and negatively modulates HCV replication. Unsaturated fatty acids play key roles in membrane curvature and fluidity. Mechanistically, we demonstrate that SCD-1 inhibition disrupts the integrity of membranous HCV replication complexes and renders HCV RNA susceptible to nuclease-mediated degradation. Our work establishes a novel function for unsaturated fatty acids in HCV replication.

7 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMarie-Eve Wedge
Marie-Eve Wedge
VJVictoria A. Jennings
Victoria A. Jennings
MCMathieu J. F. Crupi
Mathieu J. F. Crupi
JPJoanna Poutou
Joanna Poutou
TJTaylor Jamieson
Taylor Jamieson
CICarolina Ilkow
Carolina Ilkow
Recent advances in cancer therapeutics clearly demonstrate the need for innovative multiplex therapies that attack the tumour on multiple fronts. Oncolytic or “cancer-killing” viruses (OVs) represent up-and-coming multi-mechanistic immunotherapeutic drugs for the treatment of cancer. In this study, we perform an in-vitro screen based on virus-encoded artificial microRNAs (amiRNAs) and find that a unique amiRNA, herein termed amiR-4, confers a replicative advantage to the VSVΔ51 OV platform. Target validation of amiR-4 reveals ARID1A, a protein involved in chromatin remodelling, as an important player in resistance to OV replication. Virus-directed targeting of ARID1A coupled with small-molecule inhibition of the methyltransferase EZH2 leads to the synthetic lethal killing of both infected and uninfected tumour cells. The bystander killing of uninfected cells is mediated by intercellular transfer of extracellular vesicles carrying amiR-4 cargo. Altogether, our findings establish that OVs can serve as replicating vehicles for amiRNA therapeutics with the potential for combination with small molecule and immune checkpoint inhibitor therapy.

1 February 2011 in Virology
Verified
Journal Article
Closed access
NNNeda Nasheri
Neda Nasheri
RSRagunath Singaravelu
Ragunath Singaravelu
MGMatthew Goodmurphy
Matthew Goodmurphy
RLRodney K. Lyn
Rodney K. Lyn
JPJohn Paul Pezacki
John Paul Pezacki